{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:30:34Z","timestamp":1788280234886,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/mph.0b013e31822d4d4e","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T15:43:40Z","timestamp":1319816620000},"page":"610-616","source":"Crossref","is-referenced-by-count":49,"title":["Polyethylene Glycol-conjugated L-asparaginase Versus Native L-asparaginase in Combination With Standard Agents for Children With Acute Lymphoblastic Leukemia in Second Bone Marrow Relapse"],"prefix":"10.1097","volume":"33","author":[{"given":"Joanne","family":"Kurtzberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Asselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Camitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210227","first-page":"466","article-title":"L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow.","volume":"30","author":"Ho","year":"1970","journal-title":"Cancer Res"},{"key":"R2-8-20210227","first-page":"2619","article-title":"Inhibition of leukemia in man by L-asparaginase.","volume":"27","author":"Oettgen","year":"1967","journal-title":"Cancer Res"},{"key":"R4-8-20210227","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/1097-0142(196612)19:12<1813::AID-CNCR2820191208>3.0.CO;2-E","article-title":"Toxic and antineoplastic effects of L-asparaginase.","volume":"19","author":"Dolowy","year":"1966","journal-title":"Cancer"},{"key":"R5-8-20210227","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJM196911062811902","article-title":"L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.","volume":"281","author":"Haskell","year":"1969","journal-title":"N Engl J Med"},{"key":"R6-8-20210227","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","article-title":"L-asparaginase: clinical, biochemical, pharmacological, immunological studies.","volume":"74","author":"Capizzi","year":"1971","journal-title":"Ann Intern Med"},{"issue":"suppl 4","key":"R7-8-20210227","first-page":"101","article-title":"L-asparaginase as a single agent in acute lymphoblastic leukemia: survey of studies from the Childrens Cancer Study Group.","volume":"65","author":"Nesbit","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"R8-8-20210227","first-page":"269","article-title":"Treatment of adult leukemia with L-asparaginase (NSC-109229).","volume":"55","author":"Ohnuma","year":"1971","journal-title":"Cancer Chemother Rep"},{"key":"R9-8-20210227","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H","article-title":"E. coli asparaginase in the treatment of leukemia and solid tumors in 131 children.","volume":"25","author":"Tallal","year":"1970","journal-title":"Cancer"},{"key":"R10-8-20210227","first-page":"9","article-title":"Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.","volume":"1","author":"Nesbit","year":"1979","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R11-8-20210227","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/mpo.2950060408","article-title":"Vincristine and prednisone versus vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children.","volume":"6","author":"Herson","year":"1979","journal-title":"Med Pediatr Oncol"},{"key":"R12-8-20210227","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/1097-0142(19800615)45:12<3090::AID-CNCR2820451235>3.0.CO;2-F","article-title":"Improved treatment results in the management of single and multiple relapses of acute lymphocytic leukemia.","volume":"45","author":"Reaman","year":"1980","journal-title":"Cancer"},{"key":"R13-8-20210227","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1182\/blood.V72.4.1286.1286","article-title":"Reinduction therapy in 273 children with acute lymphoblastic leukemia (ALL) in first bone marrow relapse: a Pediatric Oncology Group Study.","volume":"72","author":"Buchanan","year":"1988","journal-title":"Blood"},{"key":"R14-8-20210227","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.","volume":"39","author":"Ertel","year":"1979","journal-title":"Cancer Res"},{"key":"R15-8-20210227","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/(SICI)1096-911X(199710)29:4<256::AID-MPO4>3.0.CO;2-L","article-title":"Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite-based chemotherapy.","volume":"29","author":"Barredo","year":"1997","journal-title":"Medical Pediatr Oncol"},{"key":"R16-8-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<233::AID-MPO5>3.0.CO;2-H","article-title":"High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Childrens Cancer Group Experience.","volume":"30","author":"Harris","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"R17-8-20210227","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1701223","article-title":"Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.","volume":"21","author":"Graham","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R18-8-20210227","first-page":"5601","article-title":"Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.","volume":"43","author":"Sallan","year":"1983","journal-title":"Cancer Res"},{"key":"R19-8-20210227","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM198609113151101","article-title":"Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.","volume":"315","author":"Clavell","year":"1986","journal-title":"N Engl J Med"},{"key":"R20-8-20210227","first-page":"459","article-title":"More is better! Update of Dana-Farber Cancer InstituteChildrens Hospital childhood acute lymphoblastic leukemia trials.","volume":"33","author":"Sallan","year":"1990","journal-title":"Haematol Blood Transfus"},{"key":"R21-8-20210227","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","article-title":"Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer InstituteChildrens Hospital acute lymphoblastic leukemia consortium protocol 85-01.","volume":"12","author":"Schorin","year":"1994","journal-title":"J Clin Oncol"},{"key":"R22-8-20210227","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.1998.16.8.2840","article-title":"Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group Study.","volume":"16","author":"Harris","year":"1998","journal-title":"J Clin Oncol"},{"key":"R23-8-20210227","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"R24-8-20210227","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL.","volume":"28","author":"Muller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"R25-8-20210227","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/10428199309149127","article-title":"Asparaginase revisited.","volume":"10","author":"Capizzi","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"R26-8-20210227","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/1097-0142(197610)38:4<1843::AID-CNCR2820380463>3.0.CO;2-J","article-title":"Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures.","volume":"38","author":"Dellinger","year":"1975","journal-title":"Cancer"},{"key":"R27-8-20210227","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1097-0142(197208)30:2<339::AID-CNCR2820300206>3.0.CO;2-P","article-title":"Toxicity of L-asparaginase in children with advanced leukemia.","volume":"30","author":"Land","year":"1972","journal-title":"Cancer"},{"key":"R28-8-20210227","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M","article-title":"Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.","volume":"70","author":"Billett","year":"1992","journal-title":"Cancer"},{"key":"R29-8-20210227","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","article-title":"Toxicity of E. coli asparaginase in man.","volume":"25","author":"Oettgen","year":"1979","journal-title":"Cancer"},{"key":"R30-8-20210227","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/1097-0142(19820401)49:7<1378::AID-CNCR2820490713>3.0.CO;2-Z","article-title":"Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.","volume":"49","author":"Evans","year":"1982","journal-title":"Cancer"},{"key":"R31-8-20210227","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MPH.0b013e3181483df1","article-title":"Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Childrens Oncology Group study.","volume":"29","author":"Wacker","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"R32-8-20210227","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/1097-0142(197403)33:3<611::AID-CNCR2820330303>3.0.CO;2-U","article-title":"Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. Coli L-asparaginase.","volume":"33","author":"King","year":"1974","journal-title":"Cancer"},{"key":"R33-8-20210227","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/1097-0142(197208)30:2<376::AID-CNCR2820300212>3.0.CO;2-4","article-title":"Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. Coli.","volume":"30","author":"Ohnuma","year":"1972","journal-title":"Cancer"},{"key":"R34-8-20210227","first-page":"1927","article-title":"Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.","volume":"39","author":"Uren","year":"1979","journal-title":"Cancer Res"},{"key":"R35-8-20210227","first-page":"1127","article-title":"Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.","volume":"63","author":"Abuchowski","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"R36-8-20210227","first-page":"175","article-title":"Cancer therapy with chemically modified enzymes I: antitumor properties of polyethylene glycol-asparaginase conjugates.","volume":"7","author":"Abuchowski","year":"1984","journal-title":"Cancer Biochem Biophys"},{"key":"R37-8-20210227","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","article-title":"Open-label, multicenter study of PEG-Lasparaginase for the treatment of acute lymphoblastic leukemia.","volume":"75","author":"Ettinger","year":"1995","journal-title":"Cancer"},{"key":"R38-8-20210227","first-page":"206a","article-title":"International multicenter study of PEG-L-asparaginase for reinduction therapy for children with acute lymphoblastic leukemia.","volume":"80","author":"Kurtzberg","year":"1992","journal-title":"Blood"},{"key":"R39-8-20210227","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations.","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"key":"R40-8-20210227","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases: comparative pharmacology and optimal use in childhood leukemia.","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"R41-8-20210227","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"key":"R42-8-20210227","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","article-title":"Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study.","volume":"96","author":"Abshire","year":"2000","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e31822d4d4e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:53Z","timestamp":1786048193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-201112000-00008"}},"subtitle":["A Children's Oncology Group Study (POG 8866)"],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e31822d4d4e","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}